NEW YORK (GenomeWeb News) — Investment bank Cowen & Co. today downgraded shares of Illumina to "Neutral" from "Outperform."
Reuters today reported that Cowen said the shares "appear reasonably valued, noting the firm's shares were up 154 percent year-to-date."
Reuters reported that the brokerage said "many investors agree with its view that Illumina's high-throughput genotyping technology is best in class."
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.